Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Brakch N et al. – Sphingosine–1 phosphate participates in cardiovascular remodelling in Fabry disease. These findings have implications for the treatment of cardiovascular involvement in Fabry disease.

   

Related Articles

End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry
Nephrology Dialysis Transplantation, 11/05/09    Relevance Score: 69%

A case of minimal change disease in a Fabry patient
Pediatric Nephrology, 11/04/09    Relevance Score: 68%

Effect of agalsidase alfa replacement therapy on fabry disease—related hypertrophic cardiomyopathy: A 12- to 36-month, retrospective, blinded echocardiographic pooled analysis
Clinical Therapeutics, 10/29/09    Relevance Score: 68%

Aortic remodelling in Fabry disease
European Heart Journal, 10/26/09    Relevance Score: 68%

Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN)
Nephrology Dialysis Transplantation, 10/16/09    Relevance Score: 68%

Today in Vascular Medicine...keeping you current

Liquid versus foam sclerotherapy
Phlebology, 12/04/09

Foam sclerotherapy: cardiac and cerebral monitoring
Phlebology, 12/04/09

Is Moderate Atherosclerotic Stenosis in the Middle Cerebral Artery a Cause of or a Coincidental Finding in Ischemic Stroke
Cerebrovascular Diseases, 12/04/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address